YAFO Capital (Shanghai) Announces Expansion in Europe and Joint Venture with FCF Fox Corporate Finance

Shanghai/Munich, June 18, 2020 – The Life Sciences team at YAFO Capital is expanding its European network with a new joint venture. Germany advisory firm FCF Fox Corporate Finance is the most recent addition to the roster of renowned international partners working with the Shanghai-based life science specialist. “We look forward to expanding our partnership with FCF and providing the best landing platform for European biopharma and medtech companies to access China, as well as helping YAFO’s Chinese biopharma clients to access Europe.” says Sean Jiang, CEO & Founder of YAFO Capital. “Over the last seven years, YAFO has built a solid institutional investor base and broad coverage of over 500 pharma, biotech, and medtech companies in Asia. We hope our investor base and expertise can benefit European companies when penetrating the Asian market.“ comments Fan Zheng, Managing Director of YAFO Life Science.

Munich-based FCF Fox Corporate Finance specializes in providing investment banking services for listed and non-listed small to midsized enterprises in German-speaking Europe. Thanks to YAFO’s stellar connections in the biotech industry in China, FCF stands to benefit from having a reliable partner on the ground in Shanghai with long-standing expertise in Life Science transactions.

“Our joint venture with YAFO Capital will open up access to a huge pool of investors in China and throughout Asia, as our other partnerships have done for many years in regions such as the US,” says Arno Fuchs, CEO of FCF Fox Corporate Finance. “Now more than ever, Chinese investors are emerging as a key source of capital,” notes Dr. Mathias Schott, Director of FCF Life Sciences, “which makes this market an important factor in our efforts to help European Life Sciences enterprises attract global investors. By partnering with YAFO, FCF is taking another important step in this direction.”

Building on the positive experiences and successes of their first joint pilot projects, the new venture will collaborate on business development initiatives in products and licensing, market research, joint road shows and, most importantly, key financing and strategic deals. Our initial projects as partners have shown that we are in a good position to build a bridge between Asia clients and Life Science communities in Europe, which will continue to be the focus of the partnership moving forward.

YAFO has built an international team including rep-offices in Los Angeles and London headed by Kun Tao, Partner & Head of YAFO US operations, and Gian Dell Antonio, Europe Business Development Manager. YAFO initiated its Israel business back to 2014. Then, YAFO continued to expand its global Life Science presence after establishing YAFO-HekaBio strategic alliance in Tokyo last year.

About YAFO Capital and YAFO Life Science

Founded in 2013, YAFO Capital is a Shanghai-based investment and advisory boutique focused on Life Science. YAFO is dedicated to bringing global pharmaceutical and medical device products to China and the rest of Asia. Currently, with more than 20 experts working out of its offices in China, US, Japan and the UK, YAFO operates through its two divisions: YAFO Life Science (YLS, advisory) and YAFO Fund Management (AMAC licensed).

YAFO Life Science is the investment banking division of YAFO Capital with a focus on global biopharma that provides advisory services for Licensing, Capital Raising, and M&A.

YAFO ACCESS CHINA Forum - The most effective deal-making platform for Western pharma and biotech leaders looking to enter or expand in the Chinese market. ACCESS CHINA creates invaluable BD opportunities by directly connecting and meeting with the right partners for development, licensing, and commercial collaborations.

About FCF FOX CORPORATE FINANCE

FCF is an investment bank and corporate financing specialist for listed and non-listed small to midsized enterprises in German-speaking Europe. In Life Sciences, FCF focuses on the innovators with developing cutting-edge biotechnology, medical and health technology as well as pharmaceutical solutions.

FCF structures, manages and secures equity and debt financing solutions, providing its clients with the support they need to bring their growth strategies to fruition, whether the focus is on pre-IPO, IPO and M&A deals or financing and refinancing. Building on long-standing experience with more than 100 transactions and a total financing volume of over four billion euros, FCF advises companies in a wide range of financing issues, including matters relating to the current coronavirus crisis. Munich-based FCF was founded in 2005 and has direct ties to leading German, European and international financiers, lenders and investors focused on the German market.

Media Contact

Wendi Xiang, Tel: +86-137-3368-5995
Mail: wxiang@yafocapital.com

Contact

YAFO Capital (Shanghai) Co. Ltd 雅法资本      South Suzhou Road 1305

T: +86 136-2197-9227                 200003 Shanghai

F: +86 21 5306 9110                    http://www.yafocapital.com

Email: QLI@yafocapital.com

FCF Fox Corporate Finance GmbH      Maximilianstrasse 12-14

T: +49-89-20 60 4090                     80539 München

F: +49-89-20 60 409 -299               www.fcf.de

上海雅法资本宣布与投资银行FCF Fox成立欧洲合资公司

雅法资本欧洲合资,助力中国药企全球BD

【2020年6月18日,上海/慕尼黑】雅法资本宣布:在德国慕尼黑成立新的合资公司,拓展欧洲医疗投行业务,德国投资银行FCF Fox Corporate Finance将成为雅法资本全球医疗业务(YAFO Life Science)新的国际合作伙伴。雅法资本创始人兼CEO蒋晓阳先生表示:“我们期待把与FCF现有的良好合作关系推进到新的高度并成立合资公司,为欧洲先进生物制药和医疗技术公司提供进入中国的最佳平台,同时也能够更好地帮助雅法中国生物制药企业客户进入欧洲。”雅法全球医疗业务董事总经理郑帆先生对于合资公司也寄予厚望:“在过去的七年中,雅法建立了坚实的机构客户基础,覆盖了亚洲500多家制药企业、生物技术和医疗技术公司和专业投资机构。希望我们的客户基础和专业团队能够帮助欧洲公司更好地进入亚洲”。

FCF Fox Corporate Finance总部位于德国慕尼黑,专为德语区的欧洲上市和非上市企业提供投资银行服务。而雅法在中国生物医药交易领域拥有的卓越客户关系网,将为FCF在上海提供更多更可靠的生命科学领域的专业合作伙伴。

FCF首席执行官Arno Fuchs先生表示:“我们与雅法资本的合资公司将为FCF欧洲客户打开与中国乃至整个亚洲的合作渠道,并接触本地庞大的投资和合作机构,就像我们与美国以及其他地区的合作伙伴所做的一样。”FCF生命科学总监Mathias Schott博士指出:“中国的投资者现在渐渐成为了资本的主要来源, 这使得中国市场成为我们在帮助欧洲生命科学企业吸引全球投资和合作的重要因素。通过和雅法的合作,FCF朝着这个方向正在迈出重要的一步”。

基于双方在前期项目合作上的成功经验,这家新的合资公司将在产品业务拓展、许可交易、市场研究、联合路演、重大融资和战略交易等业务进行全面合作。双方前期的项目合作成功证明了雅法与FCF可以为亚洲客户及欧洲生命科学企业之间架起良好的桥梁,这将成为新合资公司健康发展的重要基石。

经过多年的市场开拓,雅法已建立了一支国际化的专业团队,在洛杉矶和伦敦均设立了代表处,分别由雅法美国业务负责人兼公司合伙人陶锟先生和欧洲业务发展经理Gian Dell Antonio负责。2014年,雅法开始启动以色列医疗业务;2018年在米兰建立了YAFO-CrossBorder联合投行团队;2019年在东京与日本战略合作伙伴建立了YAFO-HekaBio联盟,雅法将继续致力于扩大其全球生命科学业务,助力中国药企全球BD,引入更多海外优质产品。

关于雅法资本和雅法全球医疗

雅法资本成立于2013年,是一家总部位于上海的投资公司和专注于生命科学领域交易和咨询的精品投行。雅法全球医疗(YAFO Life Science)是雅法资本旗下医疗大健康部门,专注于帮助具有“中国角度”的海外医药、医疗企业在中国的拓展、融资、授权和战略合作;潜心为中国医疗企业提供海外市场融资及双向市场授权机会。雅法致力于成为全球医疗技术对接中国市场与资本的桥梁,目前业务覆盖以色列、美国、瑞士、英国、日本等八个医疗创新能力最强的国家。 雅法全球医疗专注以下业务:

1. 卖方投行业务:帮助海内外先进医药、医疗科技公司在中国及境外的融资、并购和产品授权(licensing)等;

2. 买方顾问服务:为中国医药及医疗企业提供海外市场咨询服务,寻找海外投资、并购标的以及协助达成商业授权合作;

3. 基金投资:与战略伙伴建立私募股权基金,投资引进成熟海外医疗技术和项目。

关于FCF FOX CORPORATE FINANCE

FCF是一家欧洲投资银行和企业融资公司,服务于欧洲德语区上市和非上市企业。在生命科学领域,FCF专注创新技术,包括先进的生物技术、医疗技术和健康服务以及创新药物解决方案。

FCF提供交易架构、股权及债务融资解决方案,无论是对于上市前、上市、并购交易还是融资和再融资,都为客户提供实现其增长型战略目标所需的支持。凭借其超过100笔的过往交易经验和40多亿欧元的融资纪录,FCF为企业提供广泛的融资咨询服务,也包括当前新冠状病毒危机所带来的相关交易需求。FCF成立于2005年,总部位于德国慕尼黑,与专注于德国市场的德国、欧洲及国际领先的金融机构、贷方和投资者建立了紧密的合作。

媒体联系

相文迪 Wendi, 电话:+86 137-3368-5995
邮箱:wxiang@yafocapital.com

联系方式

雅法资本YAFO Capital (Shanghai)      上海市黄浦区南苏州路1305号

电话:+86 136-2197-9227                 邮编:200003

传真:+86 21 5306 9110                    http://www.yafocapital.com

Email: QLI@yafocapital.com

FCF Fox Corporate Finance GmbH      Maximilianstrasse 12-14

电话: +49-89-20 60 4090                     80539 München

传真: +49-89-20 60 409 -299               www.fcf.de